Abstract
Background: Despite adherence to maximal inhaled therapy, 5-10% of asthma patients in Canada still suffer from poorly controlled symptoms. These severe asthma patients have frequent exacerbations as well as increased morbidity and mortality, not only associated with the disease but in some cases the medications used to treat it. Asthma patients often rely on the use of short-acting beta-2 agonists and oral corticosteroids to manage their symptoms on a day-to-day basis. Overuse of these medications is problematic, as patients are at an increased risk of treatment related side effects. Overuse also suggests uncontrolled asthma which could be due to the presence of undiagnosed severe asthma. The objective of this commentary is to describe the asthma crisis in Canada, followed by consensus-based recommendations on best practices for its treatment and management, and their implementation.
Consensus Recommendations: Previous consensus-based research has highlighted areas where changes in care are most required. Core recommendations from this research aim to shift care to a more proactive approach, where healthcare providers think critically about patients whose asthma is not well controlled in addition to educating patients on their condition, and empowering them to seek care if their symptoms worsen.
Implementing Change: To successfully implement the proposed changes will require a concerted effort from all stakeholders. The core recommendations can be actioned at each level of the healthcare pathway, and include input from respiratory specialists (including respirologists, allergists, respiratory educators), nurses, pharmacists, general practitioners, and patients.
Conclusions: The core recommendations outlined can be easily implemented across the asthma and severe asthma treatment pathways in Canada. Taking a more proactive approach to severe asthma has the potential to improve patient outcomes through earlier diagnosis and treatment, whilst alleviating pressure on the health system.
Keywords
Best practice, Biologics, Consultation and referral, Primary care, Health care, Canada